Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC
PMID 42006277 | Phase 3 RCT addendum / biomarker sub-study | 🔴 EARLY_CANCER_DETECTION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | cfDNA/liquid biopsy in EGFR NSCLC is an active area, but mutation-specific predictors of ramucirumab benefit from a Phase 3 dataset is a meaningful and specific advance over prior work |
| Clinical Relevance | 8 | Directly actionable: identifies which EGFR-mutated NSCLC patients derive benefit from adding ramucirumab to erlotinib; Phase 3 setting confers strong translational weight |
| Population Reach | 7 | EGFR-mutated NSCLC is the most common targetable NSCLC subset globally (~30–50% in Asian populations, ~15% in Western); large absolute patient numbers |
| Implementation Speed | 7 | Liquid biopsy is already widely available in NSCLC clinics; companion diagnostic framework could integrate into existing cfDNA workflows relatively quickly |
| Evidence Strength | 8 | Anchored in Phase 3 RCT (RELAY) with prospectively collected biosamples; sub-study design is a limitation but derives legitimacy from the parent trial's rigor |
Key quantitative result: Mutation-specific cfDNA profiles predict differential benefit from ramucirumab — specific effect sizes not extractable from abstract metadata; full text available (PMC13091193).
External validation: Embedded in RELAY Phase 3 RCT framework; Japan cohort sub-study, so generalizability to non-Asian populations is a limitation.
Main limitation: Sub-study/addendum design means sample size may be underpowered for all mutation subtypes; Japan-only cohort limits ethnic and genomic diversity generalizability.
Equity implications: Japanese/East Asian populations with high EGFR mutation prevalence are well-served. Western and other non-Asian NSCLC populations underrepresented; real-world implementation will require validation in ethnically diverse cohorts.
Evidence Maturity: Confirmed — Potentially Practice-Changing ✓
Article 2 — Whole-genome sequencing of cell-free DNA for MRD in smoldering multiple myeloma
PMID 42007449 | Validation study | 🔴 EARLY_CANCER_DETECTION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | WGS-based cfDNA MRD in smoldering MM (pre-malignant stage) is genuinely novel; most prior MRD work focuses on active MM using bone marrow or targeted sequencing; WGS adds structural variant resolution |
| Clinical Relevance | 8 | Non-invasive MRD monitoring without bone marrow biopsy is a major clinical need; timing intervention in high-risk smoldering MM is an unresolved and high-stakes clinical problem |
| Population Reach | 6 | Smoldering MM is a niche diagnosis (~0.8–1.3% of the population aged >45 in the US); relative to the relevant clinical population the unmet need is high given current monitoring limitations |
| Implementation Speed | 5 | WGS of cfDNA is technically demanding and costly; clinical laboratory infrastructure for this application is nascent; will require standardization and cost reduction before broad adoption |
| Evidence Strength | 7 | Validation study with WGS methodology is rigorous; sample size not reported in metadata — a meaningful limitation; single-stage validation without independent external cohort confirmation noted |
Key quantitative result: WGS cfDNA detects and monitors MRD in pre-malignant smoldering MM — quantitative sensitivity/specificity not extractable from abstract; full text available (PMC13084702).
External validation: Described as validation study; independent cohort replication not confirmed from available metadata.
Main limitation: Sample size unknown; WGS is expensive and not yet standard in clinical lab settings; clinical utility (does earlier detection change outcomes?) remains to be prospectively proven.
Equity implications: High-risk smoldering MM has disproportionate prevalence in Black Americans (2–3× higher rates of MM). WGS cfDNA testing access disparities could worsen existing inequity in early MM intervention if restricted to tertiary centers.
Evidence Maturity: Confirmed — Validated ✓ (validated methodology; clinical outcome impact still exploratory)
Article 3 — AI-based prognostic models in AML: systematic review and meta-analysis
PMID 42007253 | Systematic review and meta-analysis | 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI prognostics in AML has a growing literature; an SR/MA synthesizing this evidence is timely but not itself a discovery — it consolidates and quantifies rather than discovering new biology |
| Clinical Relevance | 7 | AML has one of the poorest prognoses of any hematologic malignancy; validated AI tools that outperform ELN risk classification have clear pathway to improve treatment allocation |
| Population Reach | 6 | AML incidence ~4/100,000; serious disease but relatively rare in absolute terms; however, prognostic accuracy affects nearly every AML patient at diagnosis |
| Implementation Speed | 7 | SR/MA provides the evidence foundation needed for clinical adoption; AI prognostic tools are already being embedded in EHR/LIS platforms — this evidence could accelerate integration |
| Evidence Strength | 8 | SR/MA is the highest evidence synthesis design; pooled discrimination metrics strengthen confidence; quality depends on included study heterogeneity (not fully assessable from abstract) |
Key quantitative result: Pooled AI models demonstrate superior discrimination vs. conventional tools — specific AUC/C-statistic values not extractable from metadata; full text available (PMC13091435).
External validation: SR/MA by design pools multiple studies; individual model external validation is a known weakness in AI prognostics literature.
Main limitation: Constituent AI studies are often retrospective, single-center, and trained on heterogeneous feature sets; meta-analytic pooling may mask significant inter-study heterogeneity; publication bias toward high-performing models likely.
Equity implications: AML outcomes vary substantially by age, race, and access to specialized centers. If AI prognostic tools are validated primarily on data from academic medical centers or specific ethnic cohorts, deployment could widen disparities in risk stratification accuracy for underrepresented populations.
Evidence Maturity: Confirmed — Validated ✓
Article 4 — HemeAge and cardiovascular risk: ML analysis in two cohorts
PMID 42006429 | ML analysis; two-cohort validation | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Deriving an aging clock and CVD risk predictor from standard CBC parameters using ML is conceptually innovative; CBC has been underexplored as a multidimensional aging biomarker in this framing |
| Clinical Relevance | 7 | CVD risk stratification from existing CBC data (no additional cost) is immediately compelling; requires clinical integration and outcome-based validation before displacing established risk tools |
| Population Reach | 9 | CBC is the single most commonly ordered test globally; a validated CVD risk tool derived from CBC would be applicable to virtually any adult patient with a recent blood count |
| Implementation Speed | 8 | No new test required — model could theoretically be deployed as a software overlay on existing CBC data; regulatory pathway for a risk calculator tool (vs. diagnostic) is more tractable |
| Evidence Strength | 7 | Two-cohort validation is a meaningful strength; ML model performance in external cohorts is a key criterion; sample sizes and specific metrics not available from metadata |
Key quantitative result: HemeAge independently predicts CVD risk across two cohorts — effect sizes not extractable; full text available (PMC13084135).
External validation: Two-cohort design provides internal cross-validation; independent prospective validation not yet described.
Main limitation: Observational design cannot establish causality; cohort demographic composition unknown — potential for model miscalibration in populations not represented; implementation requires EHR integration and clinical workflow changes.
Equity implications: CBC is universally available and low-cost, making this approach theoretically equitable. However, if training cohorts are demographically homogeneous, CBC-derived aging signals (influenced by race, ancestry, comorbidities) may perform unevenly across populations.
Evidence Maturity: Confirmed — Validated ✓
Article 5 — SGLT-2 inhibitors in HFpEF: SR/MA of RCTs
PMID 42007145 | Systematic review and meta-analysis of RCTs | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | SGLT-2 inhibitors in HFpEF are now established by landmark trials (EMPEROR-Preserved, DELIVER); this SR/MA consolidates existing evidence rather than generating new findings |
| Clinical Relevance | 8 | HFpEF affects ~50% of all heart failure patients and has historically lacked proven therapies; SGLT-2 SR/MA reinforcing mortality/hospitalization benefit is clinically important for guideline alignment |
| Population Reach | 9 | HFpEF is extremely prevalent — ~3 million patients in the US alone, 30–50 million globally; cardiometabolic comorbidities make this overlap population enormous |
| Implementation Speed | 8 | SGLT-2 inhibitors are already approved, available, and prescribed; this SR/MA reduces clinical equipoise and supports expanded use; guideline inclusion is the primary remaining step |
| Evidence Strength | 8 | SR/MA of RCTs is the highest evidence tier; quality depends on included trial heterogeneity and outcome definition consistency across trials |
Key quantitative result: Significant reductions in mortality and HF hospitalizations in HFpEF — specific pooled hazard ratios not extractable from abstract; full text available (PMC13090863).
External validation: Derived from multiple independent RCTs — strong external validity by design.
Main limitation: Included trials may vary in HFpEF definition (EF thresholds, diagnostic criteria); meta-analytic averaging may obscure heterogeneity of treatment effect by patient subgroup (obesity, diabetes status, EF range).
Equity implications: HFpEF is more prevalent in women, older adults, and communities with high hypertension/obesity burden. SGLT-2 inhibitors are already included in some guidelines; access disparities (cost, insurance coverage) may limit benefit in lower-income and underinsured populations.
Evidence Maturity: Confirmed — Potentially Practice-Changing ✓
Article 6 — Tirzepatide as adjunct to insulin in T1D + obesity: systematic review
PMID 42007544 | Systematic review (RCT + real-world) | 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Tirzepatide (GIP/GLP-1 dual agonist) in T1D is an emerging and largely unlicensed indication; the systematic review of this gap fills an important evidence void |
| Clinical Relevance | 7 | T1D + obesity is a clinically challenging combination with high CVD risk; adjunct therapy reducing weight and improving glycemia without licensed options is high-value |
| Population Reach | 6 | ~8–9 million T1D patients globally; of whom ~40–50% have overweight/obesity — substantial but smaller absolute population than T2D |
| Implementation Speed | 6 | Off-label in T1D in most markets; regulatory approval requires dedicated T1D RCT data; medium-term adoption likely pending formal trial completion |
| Evidence Strength | 5 | Systematic review combining RCT and real-world evidence; medium confidence due to abstract-only access and "medium" classification_confidence; heterogeneous evidence base (RCT + RWE) reduces pooled certainty |
Key quantitative result: Improved glycemic control and weight reduction in T1D + obesity — specific metrics not extractable; abstract only.
External validation: Synthesizes multiple existing studies; individual studies in T1D with tirzepatide are small and limited.
Main limitation: Abstract-only access; limited dedicated T1D RCT data; DKA risk (known GLP-1 concern in T1D) not assessable from available metadata; small constituent studies.
Equity implications: T1D disproportionately burdens younger patients; obesity co-prevalence is increasing in T1D due to intensive insulin therapy. Access to tirzepatide is currently cost-limited globally, exacerbating disparities.
Evidence Maturity: Revised to Validated (Preliminary) — evidence base is real but thin; "Validated" overstates the current state for an off-label indication.
Article 7 — APL-like subset within NPM1-mutated AML
PMID 42007444 | Observational cohort study | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Identifying a phenotypically distinct APL-like subset within NPM1-mutated AML that predicts vascular complications is a clinically useful and novel refinement of AML subclassification |
| Clinical Relevance | 7 | Vascular complications (bleeding/thrombosis) are major early causes of AML mortality; identifying a high-risk subgroup enables targeted prophylaxis and monitoring |
| Population Reach | 5 | NPM1-mutated AML comprises ~30% of adult AML; the APL-like subset is a fraction of this group — relevant but narrow absolute population |
| Implementation Speed | 6 | Immunophenotyping is routine in AML workup; integrating this subset definition requires clinical protocol update but no new technology |
| Evidence Strength | 6 | Multicenter observational cohort is a solid design; retrospective and sample size unknown; requires prospective replication |
Key quantitative result: APL-like immunophenotype correlates with increased early vascular complications — magnitude not extractable from metadata.
External validation: Multicenter design strengthens generalizability; prospective validation not confirmed.
Main limitation: Observational, retrospective; definition of "APL-like immunophenotype" requires standardization across centers; vascular outcome ascertainment may vary.
Equity implications: AML is diagnosed across all populations; vascular risk management may be most impactful in settings where early intensive monitoring is standard (academic centers), potentially leaving community hospital patients underprotected.
Evidence Maturity: Confirmed — Validated ✓
Article 8 — cfDNA epigenomic profiling for pancreatic cancer cell-state ID
PMID 42006774 | Epigenomic biomarker discovery study | PREPRINT ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Cell-free chromatin epigenomic profiling to identify tumor cell states non-invasively is a frontier approach; application to pancreatic cancer — the hardest-to-detect major cancer — is highly significant |
| Clinical Relevance | 4 | (capped — preprint, exploratory) Potentially transformative for PDAC detection but preprint status, no peer review, no clinical performance metrics shared; cannot yet inform practice |
| Population Reach | 7 | Pancreatic cancer kills ~500,000 people/year globally; extremely poor survival due to late detection; population impact of earlier detection would be enormous |
| Implementation Speed | 3 | Preprint-stage discovery; requires peer review, clinical validation studies, regulatory approval, and assay standardization — 7–10+ year pathway |
| Evidence Strength | 5 | (capped at 7 per preprint rule, scored 5) Biomarker discovery study without peer review; methodology is sophisticated but clinical performance in early-stage PDAC unvalidated |
Key quantitative result: Distinct pancreatic cancer cell states identifiable from cfDNA chromatin profiles — quantitative metrics not extractable.
External validation: None confirmed; single-site discovery study.
Main limitation: Preprint — unreviewed; technical complexity of cell-free chromatin profiling limits near-term clinical translation; sensitivity in early-stage or localized disease unknown.
Equity implications: If successful, PDAC liquid biopsy would benefit all populations given the universally poor outcomes. Early iterations of complex assays typically reach academic centers first, potentially deepening disparities.
Evidence Maturity: Confirmed — Exploratory ✓
Article 9 — Body composition, physical function, and incident diabetes in older adults
PMID 42007503 | Prospective cohort, 14 years | 🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Body composition and physical function as diabetes predictors are well-established; 14-year follow-up in older adults adds longitudinal weight but is not conceptually novel |
| Clinical Relevance | 6 | Identifies modifiable targets (muscle mass, physical function) for diabetes prevention in older adults; actionable through exercise and nutritional interventions |
| Population Reach | 8 | Older adult diabetes is a massive global burden; aging population growth makes this increasingly relevant |
| Implementation Speed | 7 | Physical function and body composition assessment are already part of geriatric practice; findings could be integrated into preventive care guidelines relatively quickly |
| Evidence Strength | 7 | 14-year prospective cohort is methodologically strong for observational work; abstract-only access limits assessment of confounder adjustment and attrition |
Key quantitative result: Body composition and physical function independently predict 14-year diabetes incidence — specific HRs/ORs not extractable from abstract.
External validation: Single cohort; geographic and ethnic context of cohort (Chinese older adults based on authorship/journal) limits generalizability.
Main limitation: Observational — cannot exclude residual confounding; cohort may not be demographically representative of Western aging populations.
Equity implications: Older adults in LMICs carry disproportionate diabetes burden; physical function and body composition interventions are low-cost and potentially universally accessible.
Evidence Maturity: Confirmed — Validated ✓
Article 10 — IntegrateALL: RNA-seq pipeline for B-precursor ALL
PMID 42007446 | Tool validation / computational pipeline | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | An interpretable, end-to-end RNA-seq pipeline purpose-built for ALL subtype classification addresses a genuine gap; existing tools are fragmented or disease-agnostic |
| Clinical Relevance | 6 | Improved ALL subtype classification directly impacts risk stratification and treatment allocation; adoption depends on laboratory infrastructure and bioinformatics capacity |
| Population Reach | 5 | ALL is predominantly pediatric; ~6,000 new cases/year in the US; B-precursor ALL is the largest subset; high per-patient impact but small absolute numbers |
| Implementation Speed | 5 | Requires RNA-seq infrastructure and bioinformatics expertise; not all centers are equipped; medium-term adoption in specialized centers |
| Evidence Strength | 6 | Tool validation study; performance metrics not extractable from abstract; external validation cohort status unclear |
Key quantitative result: Improved subtype classification accuracy — specific metrics not available from metadata.
External validation: Described as validation study; independent cohort composition unclear.
Main limitation: Bioinformatics tool adoption faces infrastructure barriers; interpretability claims require clinical prospective validation.
Equity implications: RNA-seq-based diagnostics are not uniformly available; pediatric ALL outcomes are already better in high-resource settings; tool adoption may widen the gap with resource-limited centers.
Evidence Maturity: Confirmed — Validated ✓
Article 11 — Biological and clinical characteristics of ETV6::RUNX1-like ALL
PMID 42007448 | Multicenter retrospective cohort | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ETV6::RUNX1-like ALL is a recognized but incompletely characterized subtype; large multicenter characterization adds meaningful detail to an established category |
| Clinical Relevance | 6 | Refined molecular classification could change risk stratification for a subset of ALL patients; actionable if distinct treatment responses are confirmed |
| Population Reach | 4 | ETV6::RUNX1-like is a molecular subtype within pediatric ALL — very small absolute numbers |
| Implementation Speed | 5 | Molecular characterization tools are available but subtype-specific treatment protocols require prospective trial validation |
| Evidence Strength | 6 | Large multicenter retrospective; HemaSphere publication adds credibility; sample size unknown |
Evidence Maturity: Confirmed — Validated ✓
Article 12 — NTRK fusions and genomic landscape: real-world CGP study
PMID 42006875 | Retrospective observational, large health system | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | NTRK fusion testing and TRK inhibitors are established; characterizing the co-occurring immune/genomic landscape adds incremental precision but is not a major conceptual advance |
| Clinical Relevance | 6 | Co-occurring alterations may predict response to or resistance against TRK inhibitors; directly informs patient selection and combination therapy planning |
| Population Reach | 5 | NTRK fusions occur in ~0.5–1% of solid tumors; pan-tumor but rare; high per-patient impact given TRK inhibitor efficacy |
| Implementation Speed | 7 | Comprehensive genomic profiling with DNA+RNA is already deployed in large health systems; findings could update NTRK interpretation protocols immediately |
| Evidence Strength | 6 | Large health system real-world data provides ecological validity; retrospective and single-system limits generalizability |
Evidence Maturity: Confirmed — Validated ✓
Article 13 — Interpretable neural network on PBMC transcriptomes
PMID 42006310 | Computational/ML study | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Interpretable architecture for PBMC transcriptome risk stratification + drug target discovery is methodologically interesting; combines clinical and mechanistic utility |
| Clinical Relevance | 4 | (medium confidence, exploratory) Proof-of-concept stage; disease context and clinical performance metrics not clear from abstract |
| Population Reach | 5 | Depends entirely on which disease context is being studied — PBMC transcriptomics is applicable broadly but this application is not yet disease-specific enough to score higher |
| Implementation Speed | 3 | Transcriptomic profiling in clinical settings is not routine; significant infrastructure and validation barriers |
| Evidence Strength | 5 | Computational study without prospective clinical validation; medium classification confidence |
Evidence Maturity: Confirmed — Exploratory ✓
Article 14 — XPO1 inhibitor + venetoclax in MDS (preclinical)
PMID 42007609 | In vitro / preclinical | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | XPO1 inhibition (selinexor) + venetoclax is a rational mechanistic combination; preclinical data in MDS specifically is relatively novel |
| Clinical Relevance | 3 | (capped at 5 for non-human; scored 3) Preclinical only; MDS is an area of high unmet need but clinical translation requires phase I/II data |
| Population Reach | 5 | MDS affects ~20,000 new patients/year in the US; high-risk MDS has very poor prognosis and limited options |
| Implementation Speed | 2 | Lab-stage; clinical trials required before any patient impact |
| Evidence Strength | 4 | In vitro/ex vivo study; abstract only; no in vivo data confirmed |
Evidence Maturity: Confirmed — Exploratory ✓
Article 15 — GPER targeting in cutaneous T-cell lymphoma (preclinical)
PMID 42007255 | Preclinical (cell lines + ex vivo) | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | GPER as a therapeutic target in CTCL is genuinely novel; estrogen receptor biology in T-cell lymphoma is understudied |
| Clinical Relevance | 3 | (capped at 5 for non-human; scored 3) No clinical data; CTCL is rare with few options, but preclinical discovery is very early stage |
| Population Reach | 4 | CTCL is rare (~3,000–3,500 new US cases/year); relative unmet need is high for this population |
| Implementation Speed | 2 | Lab-stage; clinical translation pathway for novel receptor targeting is lengthy |
| Evidence Strength | 4 | Cell line + ex vivo; no in vivo data; high confidence classification but non-human caps score |
Evidence Maturity: Confirmed — Exploratory ✓
Article 16 — GLP-1 receptor agonists in acute ischemic stroke: narrative review
PMID 42006939 | Narrative review | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | GLP-1 agents in stroke prevention is an active area but not yet established; narrative review consolidates an emerging field without new data |
| Clinical Relevance | 5 | Stroke is a leading cause of death/disability; GLP-1 neuroprotection is biologically plausible and supported by some trial signals, but not yet practice-changing |
| Population Reach | 8 | Stroke affects 15 million people/year globally; GLP-1 agents are already widely prescribed — indication extension would reach enormous numbers |
| Implementation Speed | 4 | Narrative review design is low-quality evidence; dedicated RCT data needed before clinical adoption |
| Evidence Strength | 3 | Narrative review is the weakest synthesis design; no pooled effect sizes; mixed preclinical/clinical evidence |
Evidence Maturity: Confirmed — Exploratory ✓
Article 17 — Automated LLM evaluation for rare disease patient questions
PMID 42007479 | Validation study | 🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Automated LLM evaluation frameworks are an active area; application to rare disease patient support is a useful and targeted application |
| Clinical Relevance | 4 | Indirect patient impact — evaluates AI tool quality rather than delivering clinical intervention; meaningful for AI governance but not directly care-changing |
| Population Reach | 5 | Rare disease patients collectively number ~300 million globally (by "1 in 17" estimates); however this study addresses tool evaluation, not treatment |
| Implementation Speed | 6 | Framework could be deployed relatively quickly to support existing LLM patient-facing tools in rare disease portals |
| Evidence Strength | 6 | Validation study comparing automated vs. expert evaluation; methodology-focused with clear design; clinical outcome impact is indirect |
Evidence Maturity: Confirmed — Exploratory ✓
Article 18 — Upper GI cancer global burden, 1990–2021
PMID 42007221 | Global burden of disease analysis | 🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | GBD analyses of GI cancers are regularly published; 31-year longitudinal update adds value but is incremental |
| Clinical Relevance | 4 | Epidemiological/policy relevance rather than direct clinical care change; identifies risk factors for prevention programs |
| Population Reach | 9 | Upper GI cancers (gastric, esophageal) are top-5 causes of cancer death globally; predominantly affects LMIC populations |
| Implementation Speed | 5 | Policy translation of GBD data is slow; findings could inform national screening program prioritization |
| Evidence Strength | 7 | GBD analyses are methodologically robust with standardized modeling; 31-year trend data adds confidence |
Evidence Maturity: Confirmed — Validated ✓
PHASE 3 — Ranking
Conflicts and Tensions in the Literature
No direct head-to-head contradictions exist within this batch. However, two thematic tensions are worth noting:
AI prognostics in hematology (Articles 3 and 10): Article 3 provides meta-analytic evidence that AI outperforms conventional AML prognostics, while Article 10 (IntegrateALL) validates a specific RNA-seq classification tool for ALL. These are complementary but represent different stages of AI readiness — meta-analytic consolidation vs. tool-specific validation. The former provides stronger population-level evidence; the latter is closer to clinical deployment.
SGLT-2 in HFpEF (Article 5) vs. tirzepatide in T1D (Article 6): Both are SR/MA-level cardiometabolic studies but at different evidence maturity stages. SGLT-2/HFpEF evidence is mature and near-implementation; tirzepatide/T1D evidence is promising but at an earlier regulatory and clinical stage.
Ranked Table
| Rank | Article | Impact Score | Clinical Relevance (30%) | Population Reach (25%) | Scientific Novelty (20%) | Implementation Speed (15%) | Evidence Strength (10%) | Triage Score | Study Design | Priority Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| #1 | 5. SGLT-2 inhibitors in HFpEF | 7.55 | 8 | 9 | 5 | 8 | 8 | 8 | SR/MA of RCTs | 🟢 |
| #2 | 4. HemeAge CBC-ML cardiovascular risk | 7.50 | 7 | 9 | 8 | 8 | 7 | 8 | ML; two-cohort validation | 🟢 |
| #3 | 1. Ramucirumab cfDNA in EGFR NSCLC | 7.40 | 8 | 7 | 7 | 7 | 8 | 8 | Phase 3 RCT addendum | 🔴 |
| #4 | 2. WGS cfDNA MRD in smoldering MM | 7.00 | 8 | 6 | 8 | 5 | 7 | 8 | Validation study | 🔴 |
| #5 | 3. AI prognostic models in AML (SR/MA) | 6.85 | 7 | 6 | 6 | 7 | 8 | 8 | SR/MA | 🟠 |
| #6 | 6. Tirzepatide in T1D + obesity | 6.45 | 7 | 6 | 7 | 6 | 5 | 8 | Systematic review (RCT+RWE) | 🟠 |
| #7 | 8. cfDNA epigenomic profiling, PDAC | 6.05 | 4 | 7 | 9 | 3 | 5 | 7 | Preprint; biomarker discovery | ⚪ |
| #8 | 7. APL-like subset in NPM1-mutated AML | 6.00 | 7 | 5 | 7 | 6 | 6 | 7 | Observational cohort | 🟢 |
| #9 | 9. Body composition and diabetes in older adults | 6.00 | 6 | 8 | 4 | 7 | 7 | 7 | Prospective cohort, 14 yr | 🟡 |
| #10 | 10. IntegrateALL RNA-seq pipeline for ALL | 5.75 | 6 | 5 | 7 | 5 | 6 | 7 | Tool validation | 🟢 |
| #11 | 16. GLP-1 in ischemic stroke | 5.40 | 5 | 8 | 5 | 4 | 3 | 5 | Narrative review | ⚪ |
| #12 | 12. NTRK fusions + genomic landscape | 5.40 | 6 | 5 | 5 | 7 | 6 | 6 | Retrospective observational | 🟢 |
| #13 | 18. Upper GI cancer global burden | 5.30 | 4 | 9 | 4 | 5 | 7 | 5 | GBD analysis | 🟡 |
| #14 | 11. ETV6::RUNX1-like ALL characterization | 5.20 | 6 | 4 | 6 | 5 | 6 | 6 | Multicenter retrospective | ⚪ |
| #15 | 13. Interpretable NN on PBMC transcriptomes | 4.65 | 4 | 5 | 7 | 3 | 5 | 6 | Computational/ML | ⚪ |
| #16 | 17. LLM evaluation for rare disease patients | 4.65 | 4 | 5 | 6 | 6 | 6 | 5 | Validation study | 🟡 |
| #17 | 15. GPER targeting in CTCL (preclinical) | 3.55 | 3 | 4 | 7 | 2 | 4 | 5 | Preclinical | ⚪ |
| #18 | 14. XPO1 inhibitor + venetoclax in MDS (preclinical) | 3.30 | 3 | 5 | 6 | 2 | 4 | 5 | In vitro/preclinical | ⚪ |
Impact Score formula: (Clinical Relevance × 0.30) + (Population Reach × 0.25) + (Scientific Novelty × 0.20) + (Implementation Speed × 0.15) + (Evidence Strength × 0.10)
Rank Justifications
#1 — SGLT-2 inhibitors in HFpEF 🟢 This SR/MA of RCTs earns the top rank by combining the highest evidence design tier with the largest addressable patient population in this batch. HFpEF affects tens of millions globally and has historically resisted treatment — SGLT-2 inhibitors are now the most robustly supported pharmacological intervention for this phenotype. The meta-analytic consolidation directly removes the last major barrier to universal guideline adoption and clinical implementation, where drugs are already available and prescribed for other indications. The combination of high clinical relevance, enormous reach, and near-term implementability creates the strongest composite score.
Why it matters: Millions of HFpEF patients currently receive inconsistent SGLT-2 inhibitor prescribing — this SR/MA provides the evidence base to close that gap.
#2 — HemeAge CBC-ML cardiovascular risk 🟢 A two-cohort validation of a machine learning model that extracts cardiovascular risk signals from a test virtually every adult receives ranks second due to unmatched population reach and implementation tractability. The novelty of reframing the CBC as a multidimensional aging/cardiometabolic biomarker is high, and the dual-cohort design provides meaningful validation signal. The primary gap is prospective outcome validation and EHR integration, but the pathway to deployment is shorter than almost any other article in this batch.
Why it matters: No new test, no new cost — just a smarter read of a blood draw that billions of people already have each year.
#3 — Ramucirumab cfDNA in EGFR NSCLC 🔴 Anchored in a Phase 3 RCT, this liquid biopsy sub-study provides mutation-specific guidance for ramucirumab use in a defined, testable patient population. cfDNA profiling is already operationally embedded in NSCLC clinical pathways, making the implementation friction relatively low. The Japan-only cohort is the key limitation that prevents a higher ranking; validation in non-Asian EGFR NSCLC cohorts is needed.
Why it matters: In EGFR-mutated NSCLC, one size does not fit all — knowing which mutation profile benefits from adding ramucirumab could meaningfully personalize first-line therapy for one of the most common actionable lung cancer subtypes.
#4 — WGS cfDNA MRD in smoldering MM 🔴 The combination of high scientific novelty, clear clinical relevance (avoiding painful, costly bone marrow biopsies in a pre-malignant condition), and a well-defined unmet need keeps this in the top tier despite the cost and infrastructure barriers of WGS. The disproportionate MM burden in Black Americans makes equity considerations particularly salient and important to address in next-stage studies.
Why it matters: For patients with smoldering myeloma waiting to see if they progress to active disease, a blood test that gives the same information as a bone marrow biopsy would be genuinely transformative.
#5 — AI prognostic models in AML (SR/MA) 🟠 The highest-quality evidence design for the AI-in-AML question, this SR/MA establishes a credible evidence foundation for integrating AI prognostics into clinical workflow. It ranks fifth rather than higher due to the known limitations of AI prognostic meta-analyses — constituent study heterogeneity, retrospective designs, and publication bias toward high-performing models. The finding is directionally strong but requires prospective implementation validation.
Why it matters: AML is diagnosed under time pressure, and prognostic errors have life-or-death consequences — validated AI tools that outperform human-derived ELN classification deserve serious clinical attention.